Traders should monitor upcoming BRIUMVI prescription trends and payer coverage decisions, as this data may drive increased physician adoption, particularly in early, high-efficacy treatment settings. Consider positioning ahead of next earnings or commercial update.
Price Chart
Executive Summary
TG Therapeutics released new post hoc pooled analysis data from its Phase 3 ULTIMATE I and II trials, showing BRIUMVI significantly reduced relapse rates and MRI activity in patients with highly active relapsing multiple sclerosis (RMS). The results, published in Neurology and Therapy, demonstrate a 70.8% reduction in annualized relapse rate and strong NEDA-3 outcomes, reinforcing BRIUMVI’s efficacy in high-risk patients.
Key Facts
- Post hoc pooled analysis of 168 patients with highly active RMS (n=88 on BRIUMVI, n=80 on teriflunomide) showed a 70.8% relative reduction in annualized relapse rate (ARR) with BRIUMVI (0.145 vs 0.496; p<0.001).
- BRIUMVI reduced Gd+ T1 lesions by 95.6% over 96 weeks and new/enlarging T2 lesions by 91.1% vs teriflunomide (p<0.001).
- NEDA-3 rates from Weeks 24–96 were 77.9% with BRIUMVI vs 16.4% with teriflunomide, representing a 4.8-fold higher likelihood of achieving disease control.
- Benefits were observed as early as Week 12 and sustained through 96 weeks.
- The data were published in Neurology and Therapy, adding scientific credibility to BRIUMVI’s clinical profile.
Financial Impact
Positive impact on future BRIUMVI revenue potential due to strong efficacy data in high-risk patients; no direct financial figures disclosed.
Risk Factors
- No direct financial or sales data provided — commercial uptake may lag clinical evidence.
- Safety concerns remain, including PML, HBV reactivation, and infusion reactions, which could limit prescribing.
- Forward-looking statements in the release are speculative and subject to commercial execution risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251730 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 3, 2026 12w ago | 8-K | $46.17 | awaiting T+60 | — | $54.17 (+17.33%) |
Jun 11, 2026 19w ago | Institutional Cluster | $49.52 $55.74 | ▲ +12.56% | ▲ +9.30% | $54.17 (+9.39%) |
Jun 3, 2026 20w ago | 8-K | $40.11 $55.72 | ▲ +38.92% | ▲ +36.42% | $54.17 (+35.05%) |
Jun 3, 2026 20w ago | Press Release | $40.11 $55.72 | ▲ +38.92% | ▲ +36.42% | $54.17 (+35.05%) |
Jun 1, 2026 21w ago | Press Release | $37.41 $55.42 | ▲ +48.14% | ▲ +46.91% | $54.17 (+44.80%) |
May 27, 2026 21w ago | 8-K | $38.82 $54.27 | ▲ +39.80% | ▲ +38.06% | $54.17 (+39.54%) |
May 6, 2026 24w ago | 8-K | $41.97 $52.03 | ▲ +23.97% | ▲ +21.91% | $54.17 (+29.07%) |
Apr 30, 2026 25w ago | Press Release | $33.78 $55.75 | ▲ +65.04% | ▲ +61.93% | $54.17 (+60.36%) |
Apr 22, 2026 26w ago | Press Release | $38.31 $54.87 | ▲ +43.23% | ▲ +38.45% | $54.17 (+41.40%) |
Apr 15, 2026 27w ago | Press Release | $34.60 $57.12 | ▲ +65.09% | ▲ +56.95% | $54.17 (+56.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers